Dr. Michael Hayden has served on AbCellera's Board of Directors since September 2019 and is the Lead Director, Chair of the Compensation Committee and a member of the Audit and Nominating and Corporate Governance Committees. He has been CEO of Prilenia Therapeutics B.V. since September 2018 and was previously Chief Scientific Officer and President of Global R&D at Teva Pharmaceutical Industries (2012-2017). He founded several biotechnology companies, including Xenon Pharmaceuticals and 89bio, and serves on the boards of Ionis Pharmaceuticals and 89bio. A Killam Professor of Medical Genetics at the University of British Columbia, he holds an M.B., Ch.B. (M.D.) and a Ph.D. in Genetics from the University of Cape Town.